Mankind Pharma share news and announcements
NSE: MANKINDBSE: 543904Pharmaceuticals & BiotechnologyMid Cap
Share price at the NSE close on 23 Oct 2026. Previous close ₹2,275.60.
- Next results date: the board meets on 26 Oct 2026 to consider: financial results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹91,390 Cr119th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
- 44.6
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.
- 5.6
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 13.4%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 12.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.38
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 6,79,10661.7% delivered
Mankind Pharma analyst meets
62 filed, newest first. Page 1 of 2.
Oct 2026
22 Oct · Analysts
22 Oct · Analysts
12 Oct · Analysts
Sep 2026
11 Sep · Analysts
Aug 2026
10 Aug · Analysts
Jul 2026
17 Jul · Analysts
Jun 2026
15 Jun · Analysts
May 2026
27 May · Analysts
20 May · Analysts
8 May · Analysts
Feb 2026
18 Feb · Analysts
4 Feb · Analysts
Jan 2026
16 Jan · Analysts
Nov 2025
13 Nov · Analysts
7 Nov · Analysts
Oct 2025
29 Oct · Analysts
Sep 2025
15 Sep · Analysts
9 Sep · Analysts
Aug 2025
27 Aug · Analysts
25 Aug · Analysts
11 Aug · Analysts
Jul 2025
18 Jul · Analysts
Jun 2025
May 2025
27 May · Analysts
Feb 2025
20 Feb · Analysts
20 Feb · Analysts
6 Feb · Analysts
6 Feb · Analysts
Jan 2025
14 Jan · Analysts
Dec 2024
4 Dec · Analysts
Nov 2024
6 Nov · Analysts
Oct 2024
25 Oct · Analysts
Sep 2024
10 Sep · Analysts
Aug 2024
13 Aug · Analysts
7 Aug · Analysts
Jul 2024
25 Jul · Analysts
May 2024
29 May · Analysts
8 May · Analysts
Mar 2024